 Celyad is a seemingly neglected immuno-oncology-focused nano-cap, liked by analysts and experts abound, but somehow overlooked by the market. Four months ago, its share price took a dive following a clinical hold in a trial of CAR-T candidate CYAD-101 in combination with Keytruda. 